Louisiana State Employees Retirement System Acquires Shares of 36,100 Vir Biotechnology, Inc. (NASDAQ:VIR)

Louisiana State Employees Retirement System acquired a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 36,100 shares of the company’s stock, valued at approximately $696,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in VIR. State Street Corp lifted its position in Vir Biotechnology by 65.9% during the first quarter. State Street Corp now owns 4,193,764 shares of the company’s stock valued at $107,864,000 after buying an additional 1,665,657 shares during the period. Renaissance Technologies LLC raised its position in shares of Vir Biotechnology by 495.8% in the 2nd quarter. Renaissance Technologies LLC now owns 562,400 shares of the company’s stock worth $14,324,000 after purchasing an additional 468,000 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Vir Biotechnology by 1,713.0% in the 2nd quarter. Principal Financial Group Inc. now owns 471,935 shares of the company’s stock worth $12,021,000 after purchasing an additional 445,904 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Vir Biotechnology by 5.8% in the 1st quarter. Vanguard Group Inc. now owns 7,758,397 shares of the company’s stock worth $199,546,000 after purchasing an additional 428,266 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Vir Biotechnology by 91.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 612,336 shares of the company’s stock worth $15,749,000 after purchasing an additional 291,785 shares during the last quarter. Hedge funds and other institutional investors own 74.97% of the company’s stock.

Insider Buying and Selling at Vir Biotechnology

In related news, Director Vicki L. Sato sold 17,915 shares of the business’s stock in a transaction that occurred on Tuesday, November 8th. The stock was sold at an average price of $27.38, for a total transaction of $490,512.70. Following the completion of the transaction, the director now directly owns 1,399,004 shares in the company, valued at approximately $38,304,729.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, major shareholder Endurance (Cayman) Ltd Svf sold 50,173 shares of the business’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $27.41, for a total transaction of $1,375,241.93. Following the completion of the transaction, the insider now directly owns 21,566,288 shares in the company, valued at approximately $591,131,954.08. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Vicki L. Sato sold 17,915 shares of the business’s stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $27.38, for a total value of $490,512.70. Following the transaction, the director now owns 1,399,004 shares of the company’s stock, valued at $38,304,729.52. The disclosure for this sale can be found here. Insiders sold a total of 817,385 shares of company stock worth $21,973,217 in the last three months. 22.40% of the stock is currently owned by company insiders.

Vir Biotechnology Stock Up 4.0 %

Vir Biotechnology stock opened at $26.05 on Friday. The business has a 50-day simple moving average of $25.95 and a two-hundred day simple moving average of $25.03. The company has a market cap of $3.47 billion, a P/E ratio of 3.07 and a beta of 0.15. Vir Biotechnology, Inc. has a 52-week low of $18.05 and a 52-week high of $41.23.

Vir Biotechnology (NASDAQ:VIRGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported $1.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $1.29. The firm had revenue of $374.56 million for the quarter, compared to the consensus estimate of $153.79 million. Research analysts anticipate that Vir Biotechnology, Inc. will post 4.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on VIR. Morgan Stanley lifted their price target on Vir Biotechnology from $15.00 to $18.00 and gave the stock an “underweight” rating in a research report on Friday, November 4th. SVB Leerink boosted their target price on Vir Biotechnology from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Friday, November 4th. Needham & Company LLC decreased their target price on Vir Biotechnology from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Friday, November 4th. Finally, TheStreet raised Vir Biotechnology from a “d” rating to a “c-” rating in a research report on Monday, October 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $52.50.

Vir Biotechnology Profile

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Further Reading

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating).

Institutional Ownership by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.